 |
上海和香港2021年6月2日 /美通社/ -- 致力于研發和商業化創新腫瘤療法的領先生物制藥公司——德琪醫藥有限公司（簡稱“德琪醫藥”，香港聯交所股票代碼：6996.HK）今日宣布，同類首款選擇性核輸出抑制劑——塞利尼索（selinexor）15項研究及成果將在2021年美國臨床腫瘤學大會（ASCO）年會上公布。此屆 ASCO 會議于6月4日至6月8日在線上召開。
線上摘要
Effects of weekly selinexor, bortezomib, dexamethasone (XVd) versus standard twice weekly bortezomib and dexamethasone (Vd) on RAS-mutated previously treated multiple myeloma (MM).
摘要編號：8027
Effects of refractory status to lenalidomide on safety and efficacy of selinexor, bortezomib, and dexamethasone (XVd) versus bortezomib and dexamethasone(Vd) in patients with previously treated multiple myeloma.
摘要編號：8024
Survival among older patients with previously treated multiple myeloma treated with selinexor, bortezomib, and dexamethasone (XVd) in the BOSTON study.
摘要編號：8019
Updated overall survival of eltanexor for the treatment of patients with hypomethylating agent refractory myelodysplastic syndrome.
摘要編號：e19037
Results of the phase 2 MARCH Study: Oral ATG-010 (Selinexor) plus low dosedexamethasone in Chinese patients with relapsed/refractory multiple myeloma (RRMM) previously treated with an immunomodulatory agent (IMiD) and a proteasome inhibitor (PI).
摘要編號：e20002
Oral selinexor, pomalidomide, and dexamethasone (XPd) at recommended phase 2 dose in relapsed refractory multiple myeloma (MM).
摘要編號：8018
SIENDO/ENGOT-EN5/GOG-3055: A randomized phase 3 trial of maintenance selinexor versus placebo after combination platinum-based chemotherapy in advanced or recurrent endometrial cancer.
摘要編號：TPS5610
Open-label phase 1 study evaluating the tolerability and anti-tumor activity of selinexor and pembrolizumab in colorectal cancer.
摘要編號：e15579
A phase 1/2 study of selinexor in combination with standard of care therapy for newly diagnosed or recurrent glioblastoma.
摘要編號：TPS2071
A phase Ib/II study of selinexor in combination with imatinib in patients with advanced gastrointestinal stromal tumor (GIST): SeliGIST/GEIS-41 trial.
摘要編號：11534
Selinexor in combination with weekly paclitaxel in patients with advanced or metastatic solid tumors: Results of an open label, single-center, multiarm phase 1b study.
摘要編號：5565
Once weekly selinexor, carfilzomib, and dexamethasone (XKd) in carfilzomib nonrefractory multiple myeloma (MM) patients.
摘要編號：8038
A randomized, open-label, phase 3 study of low-dose selinexor and lenalidomide (Len) versus len maintenance post autologous stem cell transplant (ASCT) for newly diagnosed multiple myeloma (NDMM): ALLG MM23, Sealand.
摘要編號：TPS8055
Molecular predictors of response to selinexor in advanced unresectable de-differentiated liposarcoma (DDLS).
摘要編號：11509
Selinexor containing regimens in patients with multiple myeloma (MM) previously treated with anti-CD38 monoclonal antibodies (αCD38 mAbs).
摘要編號：e20020
關于德琪醫藥
德琪醫藥有限公司（簡稱“德琪醫藥”，香港聯交所股票代碼：6996.HK）是一家以研發為驅動的生物制藥領先企業，致力于為亞太乃至全球患者提供最領先的療法，治療腫瘤及其他危及生命的疾病。自2017年正式運營以來，德琪醫藥通過合作引進和自主研發，建立了一條從臨床前到臨床階段不斷延展的豐富產品管線。目前，德琪醫藥已在多個亞太市場獲得15個臨床批件（IND），并遞交了5個新藥上市申請（NDA）。德琪醫藥將以“醫者無疆，創新永續”為愿景，專注于同類首款和同類最優療法的早期研發、臨床研究、藥物生產及商業化，解決亟待滿足的臨床需求。
